Behandlung einer symptomatischen Hypersomnie mit Solriamfetol

ZUSAMMENFASSUNG

Es wird der Fall eines 34 Jahre alten Patienten berichtet, der nach einer Epstein-Barr-Virus-Infektion eine symptomatische Hypersomnie entwickelt hat. Diese Hypersomnie konnte mit konventionellen Substanzen nicht befriedigend gebessert werden. Unter Solriamfetol kam es zu einer signifikanten Besserung der exzessiven Tagesschläfrigkeit.

ABSTRACT

We report the case of a 34 year old patient who developed a symptomatic hypersomnia after Epstein-Barr virus infection. This hypersomnia could not be relieved by conventional drugs. After starting solfriamfetol the patient experienced a significant improvement of his excessive daytime sleepiness.

Schlüsselwörter

Hypersomnie - Epstein-Barr-Virus-Infektion - Solriamfetol

Key words

Hypersomnia - Epstein-Barr virus infection - solriamfetol

Publication History

Article published online:
09 July 2021

• Literatur

• 1 American Academy of Sleep Medicine International Classification of Sleep Disorders. Third Edition. Washington: American Academy of Sleep Medicine; 2014
• 2 Guilleminault C, Mondini S. Mononucleosis and chronic daytime sleepiness. A long-term follow-up study. Arch Intern Med 1986; 146: 1333-5
• 3 Lambore S, McSherry J, Kraus AS. Acute and chronic symptoms of mononucleosis. J Fam Pract 1991; 33: 33-7
• 4 Sforza E, Hupin D, Roche F. Mononucleosis: a possible cause of idiopathic hypersomnia. Front Neurol 2018; 9: 922
• 5 Abad VC. Profile of solriamfetol in the management of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea: focus on patient selection and perspectives. Nat Sci Sleep 2021; 13: 75-9